New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
10:02 EDTWFM, STM, OSK, MIICF, MPO, MSFT, MDT, JNJ, HTWR, ENB, OFC, GLW, BEP, CIB, ANFGYOn The Fly: Analyst Downgrade Summary
Antofagasta (ANFGY) downgraded to Hold from Buy at Canaccord... Bancolombia (CIB) downgraded to Neutral from Overweight at JPMorgan... Brookfield Renewable (BEP) downgraded to Neutral from Outperform at Credit Suisse... Corning (GLW) downgraded to Hold from Buy at Stifel... Corporate Office Properties (OFC) downgraded to Neutral from Buy at ISI Group... Enbridge (ENB) downgraded to Neutral from Outperform at Credit Suisse... HeartWare (HTWR) downgraded to Sell from Neutral at Goldman... Johnson & Johnson (JNJ) downgraded to Hold from Buy at Jefferies... Medtronic (MDT) downgraded to Neutral from Overweight at JPMorgan... Microsoft (MSFT) downgraded to Hold from Buy at Deutsche Bank... Midstates Petroleum (MPO) downgraded to Hold from Buy at MLV & Co... Millicom (MIICF) downgraded to Sell from Hold at Berenberg... Oshkosh (OSK) downgraded to Accumulate from Buy at Global Hunter... STMicroelectronics (STM) downgraded to Sell from Neutral at UBS... Whole Foods (WFM) downgraded to Hold from Buy at BB&T...
News For ANFGY;CIB;BEP;GLW;OFC;ENB;HTWR;JNJ;MDT;MSFT;MPO;MIICF;OSK;STM;WFM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 14, 2014
06:32 EDTMSFTMicrosoft says hit 1M registrants to test Windows 10 preview version
Microsoft says on its Windows blog that it hit 1M registrants for the Windows Insider Program to test the preview version of Windows 10. The company says it has received 200,000 items of user feedback. Reference Link
06:02 EDTGLWCorning downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
05:39 EDTHTWRHeartWare upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
October 13, 2014
16:33 EDTMSFTMicrosoft and Salesforce.com unveil new joint solutions
Subscribe for More Information
16:04 EDTMSFTSkullcandy announces two ASTRO headsets compatible with Xbox One
Subscribe for More Information
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
13:10 EDTMSFTGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
10:08 EDTSTMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
09:22 EDTMDTMedtronic announces positive data from CoreValve ADVANCE DA Study
Subscribe for More Information
09:21 EDTSTMOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTMSFTMicrosoft Q1 results likely to beat expectations, says Bernstein
Bernstein believes that Microsoft's cloud business continues to grow, and it expects adoption of the company's cloud products to accelerate this quarter. The firm reiterates a $56 price target and Outperform rating on the shares.
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:05 EDTJNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJ, HTWREuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTMSFT, JNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTMDT, JNJBioFlorida to hold a conference
Subscribe for More Information
05:28 EDTSTMSTMicroelectronics downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use